Avanos Medical, Inc.
AVNS
$13.32
-$0.71-5.06%
| Weiss Ratings | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.93 | |||
| Price History | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -5.93% | |||
| 30-Day Total Return | -13.79% | |||
| 60-Day Total Return | -13.84% | |||
| 90-Day Total Return | -26.08% | |||
| Year to Date Total Return | -15.86% | |||
| 1-Year Total Return | -32.04% | |||
| 2-Year Total Return | -55.26% | |||
| 3-Year Total Return | -60.36% | |||
| 5-Year Total Return | -48.25% | |||
| 52-Week High % Change | -44.68% | |||
| 52-Week Low % Change | 1.52% | |||
| Price | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $25.36 | |||
| 52-Week Low Price | $13.82 | |||
| 52-Week Low Price (Date) | Apr 03, 2025 | |||
| 52-Week High Price (Date) | Sep 20, 2024 | |||
| Valuation | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 645.42M | |||
| Enterprise Value | 707.92M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -8.54 | |||
| Earnings Per Share Growth | 545.74% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.94 | |||
| Price/Book (Q) | 0.78 | |||
| Enterprise Value/Revenue (TTM) | 1.03 | |||
| Price | $13.32 | |||
| Enterprise Value/EBITDA (TTM) | 7.87 | |||
| Enterprise Value/EBIT | 15.91 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 46.00M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 844 428 2667 | |||
| Address | 5405 Windward Parkway Alpharetta, GA 30004 | |||
| Website | avanos.com | |||
| Country | United States | |||
| Year Founded | 2014 | |||
| Profitability | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 6.46% | |||
| Profit Margin | -57.00% | |||
| Management Effectiveness | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 1.95% | |||
| Return on Equity | -- | |||
| Income Statement | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 687.80M | |||
| Total Revenue (TTM) | 687.80M | |||
| Revenue Per Share | $14.95 | |||
| Gross Profit (TTM) | 381.30M | |||
| EBITDA (TTM) | 90.00M | |||
| EBIT (TTM) | 44.50M | |||
| Net Income (TTM) | -392.10M | |||
| Net Income Avl. to Common (TTM) | -392.10M | |||
| Total Revenue Growth (Q YOY) | 3.64% | |||
| Earnings Growth (Q YOY) | -3,709.09% | |||
| EPS Diluted (TTM) | -8.54 | |||
| EPS Diluted Growth (Q YOY) | -3,900.70% | |||
| Balance Sheet | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 107.70M | |||
| Cash Per Share (Q) | $2.34 | |||
| Total Current Assets (Q) | 393.40M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 828.50M | |||
| Current Ratio (Q) | 2.371 | |||
| Book Value Per Share (Q) | $18.03 | |||
| Total Assets (Q) | 1.15B | |||
| Total Current Liabilities (Q) | 165.90M | |||
| Total Debt (Q) | 170.20M | |||
| Total Liabilities (Q) | 325.70M | |||
| Total Common Equity (Q) | 828.50M | |||
| Cash Flow | AVNS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -27.50M | |||
| Cash from Financing (TTM) | -49.10M | |||
| Net Change in Cash (TTM) | 20.00M | |||
| Levered Free Cash Flow (TTM) | 107.69M | |||
| Cash from Operations (TTM) | 100.70M | |||
